Adam Paul Kafal

This inventor holds 8 USPTO granted patents and 1 published patent application and 2 EPO patents. Top assignees: Zealand Pharma A/s, Universitéde Montreal. Active years: 2021-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Adam Paul Kafal. Retrieved from https://idiyas.com/inventor/adam-paul-kafal

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 8 (Patent Applications = 1)

% Patents Active = 62.5

EPO Patents = 2 (Patent Applications = 6)

Average Co-Inventor Count = 7.2

ph-index = 2

Forward Citations = 10(Granted Patents)

Company Filing History:

Universitéde Montreal

patents

where one patent can have more than one assignee

Years Active: 2021-2026

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12760069 - Compounds targeting ALPHA4-BETA7 integrin (2026-10-13),

2. 12077611 - Cyclic peptides multimers targeting α4β7 integrin (2024-09-03),

3. 11713338 - Cyclic peptides multimers targeting α-4-β-7 integrin (2023-08-01),

4. 11286281 - Homodetic cyclic peptides targeting alpha-4-beta-7 integrin (2022-03-29),

5. 11111273 - Cyclic peptides multimers targeting alpha-4-beta-7 integrin (2021-09-07),

6. 11072616 - Cyclic peptides targeting alpha-4-beta-7 integrin (2021-07-27),

7. 11046695 - Fragment synthesis of substituted cyclic peptides (2021-06-29),

8. 10981921 - Fragment synthesis of substituted cyclic peptides (2021-04-20),

Title: Adam Paul Kafal: Innovator in Cyclic Peptides

Introduction

Adam Paul Kafal is a notable inventor based in Toronto, Canada. He has made significant contributions to the field of cyclic peptides, holding a total of seven patents. His work focuses on innovative solutions targeting specific integrins, which are crucial in various biological processes.

Latest Patents

Among his latest patents are "Cyclic peptides multimers targeting α4β7 integrin." This patent describes multimers comprising a plurality of compounds covalently linked together, with the compounds independently being of a specific formula. Another patent with a similar title further emphasizes his focus on cyclic peptides and their applications in targeting α4β7 integrin.

Career Highlights

Throughout his career, Adam has worked with esteemed organizations such as Zealand Pharma A/S and Université de Montréal. His experience in these institutions has allowed him to develop and refine his innovative ideas in the field of biochemistry and pharmaceuticals.

Collaborations

Adam has collaborated with several professionals in his field, including Manuel Perez Vazquez and Jennifer L Hickey. These partnerships have contributed to the advancement of his research and the successful development of his patents.

Conclusion

Adam Paul Kafal is a distinguished inventor whose work in cyclic peptides has the potential to impact medical science significantly. His innovative patents and collaborations highlight his commitment to advancing the field.

Profile summary based on public USPTO records.